Crisis management is in place following flooding in Auckland. More information.
Doctor of Philosophy, (Public Health)
Study Completed: 2017
College of Health
A critical analysis of New Zealand's Psychoactive Substances Act 2013 and its implementation process
The proliferation of new psychoactive substances (NPS, sometimes known as 'legal highs') has recently challenged international and national drug control systems. In response to the ongoing problems with prohibitive policy approaches to new drugs, in July 2013 New Zealand parliament passed the Psychoactive Substances Act (PSA), which established the world's first regulated legal market for NPS. Under this regime, businesses are allowed to legally manufacture and sell psychoactive products, provided they prove that their products cause no more than a low risk of harm to consumers. Implementation of the law proved challenging. An interim regulated market established under transitional provisions of the PSA was abruptly ended in May 2014 following ongoing problems with the products and public protests. Ms Rychert's mixed-methods research critically analyses the PSA and its implementation process, including challenges experienced during the interim regime. Findings provide important lessons for drug policy reform in New Zealand and other countries.
Page authorised by Web Content Manager
Last updated on Monday 04 April 2022